D57.43
Sickle-cell thalassemia beta zero with crisis
Clinical Classification Guidelines
Inclusion Terms
- HbS-beta zero with crisis
- Sickle-cell beta zero with crisis
Medical Intelligence & Overview
Sickle-cell thalassemia beta zero with crisis is a complex inherited blood disorder affecting the production and structure of hemoglobin, the protein responsible for carrying oxygen in the blood. This condition combines features of sickle-cell disease and thalassemia, leading to abnormal red blood cells that can cause blockages in blood flow, resulting in episodes known as crises. These crises can cause severe pain and potentially lead to complications if not managed properly. Understanding the underlying causes, symptoms, and diagnostic process is essential for managing this condition effectively.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting hemoglobin production and structure Inheritance of defective genes from both parents leading to sickle-cell and beta-zero thalassemia traits Presence of abnormal hemoglobin known as hemoglobin S, combined with inadequate beta-globin chains Genetic counseling and testing can identify carriers and affected individuals
Key Symptoms: Severe episodes of pain varying in intensity and duration Swelling in hands and feet Frequent infections due to spleen complications Fatigue and weakness resulting from anemia Jaundice or yellowing of the skin and eyes Delayed growth and puberty in children Delayed wound healing and increased susceptibility to infections Potential organ damage over time, including the liver, heart, and kidneys
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of blood tests and genetic analysis. Key diagnostic steps include: - Complete blood count (CBC) to evaluate anemia levels - Hemoglobin electrophoresis to identify abnormal hemoglobin types - Genetic testing to detect mutations associated with sickle-cell disease and beta-zero thalassemia - Blood smear examinations to observe the shape of red blood cells Early diagnosis, especially through newborn screening programs, is crucial for timely management and intervention.
Treatment Protocols: While there is no universal cure for sickle-cell thalassemia beta zero with crisis, several management strategies aim to reduce symptoms and prevent complications: - Pain management during crises with medications - Regular blood transfusions to reduce the number of sickled cells - Use of medications such as hydroxyurea to decrease the frequency of crises - Antibiotics and vaccinations to prevent infections - Monitoring organ function and addressing any complications early - Bone marrow or stem cell transplants may be considered in select cases - Lifestyle adjustments, including adequate hydration, avoiding extreme temperatures, and managing stress, can help reduce crisis episodes A multidisciplinary approach involving hematologists, genetic counselors, and other healthcare professionals is essential for comprehensive care.
Clinical Advice & FAQs
Billing Guidance
Is D57.43 a billable ICD-10 code?
Yes, D57.43 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.43?
Clinical documentation must specify the nature of Sickle-cell thalassemia beta zero with crisis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference